Sharpunkha has been reported to possess anti-hyperlipidemic and hepatoprotective activity. In an experimental study, it brought about significant reduction in serum aspartate aminotransaminase, alanine aminotransaminase, gamma glutamyl transpeptidase, alkaline phosphatase, total bilirubin, and liver MDA levels, and significant improvement in liver glutathione, when compared with thioacetamide damaged rats.
Kakamachi has been reported to possess hepato-protective, anti-tumor, cytostatic, anti-convulsant, anti-ulcerogenic, anti-inflammatory effects. In addition, it is diuretic, protects kidneys, and is anti-edematous. In an experimental study, its ethanol extract showed remarkable hepatoprotective activity against CCI4 -induced hepatic damage in rats.
Bhumi-amalaki has been reported to protect the liver and reduce elevated SGPT, alkaline phosphatase (APT), and lipid peroxidation; and restore superoxidase dismutase (SOD), catalase (CAT), and glutathione-S-transferase (GST) to almost normal levels. It is effective against Hepatitis B and HIV. It lowers raised total & LDL cholesterol and triglycerides, raised blood sugar, raised blood pressure, raised serum uric acid, and eliminates / dissolves urinary calculi. In a preliminary study, carriers of hepatitis B virus were treated with a Bhumi-amalaki for 30 days. 22 of 37 (59%) treated patients had lost hepatitis B surface antigen when tested 15-20 days after the end of the treatment compared with only 1 of 23 (4%) placebo-treated controls. Some subjects have been followed for up to 9 months. In no case has the surface antigen returned. Clinical observation revealed few or no toxic effects. In another study, it was found to suppress HBV mRNA transcription in vitro and exhibits therapeutic potential in chronic HBV carriers. Analysis in HuH-7 cells with transfected plasmids using a luciferase reporter showed that Bhumi-amalaki specifically inhibited HBV enhancer I activity. Exposure to Bhumi-amalaki inhibited C/EBPα- and β-mediated up-regulation of HBV enhancer I activity in a dose-dependent manner, whereas HNF-3α- and β-mediated up-regulation of HBV enhancer I was unaffected.
LIVIE Tablet helps in keeping the blood thin by prolonging the Prothrombin Time. It should, therefore, be avoided while taking anticoagulant medicines.